Interpace Diagnostics Group (PF42) Stock Statistics & Valuation Metrics

Interpace Diagnostics Group has a market cap or net worth of €40.14M. The enterprise value is €42.20M.

Interpace Diagnostics Group has 27,700,905 shares outstanding. The number of shares has decreased by -2.65% in one year.

Interpace Diagnostics Group’s return on equity (ROE) is 1.10 and return on invested capital (ROIC) is 14.00%.

The current PE Ratio of Interpace Diagnostics Group is 0.3. Interpace Diagnostics Group’s PEG ratio is 0.00076.

In the last 12 months, Interpace Diagnostics Group had revenue of 38.73M and earned 24.57M in profits. Earnings per share was 5.55.

In the last 12 months, operating cash flow was 4.88M and capital expenditures -497.00K, giving a free cash flow of 4.38M billion.

Interpace Diagnostics Group pays an annual dividend of ―, resulting in a dividend yield of ―

Interpace Diagnostics Group upcoming earnings date is Aug 12, 2026, After Close (Confirmed).

Interpace Diagnostics Group as a current ratio of 1.94, with Debt / Equity ratio of 4.68%

In the past 12 months, Interpace Diagnostics Group has paid -21.21M in taxes.

Interpace Diagnostics Group EV to EBITDA ratio is 0.86, with an EV/FCF ratio of 0.75.

Interpace Diagnostics Group has €2.65M in cash and marketable securities with €1.08M in debt, giving a net cash position of €1.57M billion.

Gross margin is 62.53%, with operating margin of 10.55%, and net profit margin of 63.46%.

The average price target for Interpace Diagnostics Group is ―, which is 11.43% higher than the current price. The consensus rating is ―